Expectations and challenges in the therapeutic use of neurotrophic factors

Annals of Neurology

Volumn 59, Issue 3, 2006, Pages 444-447

  Kotzbauer, Paul T ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; FLUORINE 18; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; NEURTURIN; SOMATOMEDIN C;

ALZHEIMER DISEASE; ANOREXIA; CELL SURVIVAL; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; DRUG USE; EDITORIAL; EXPECTATION; GENE THERAPY; HUMAN; HUNTINGTON CHOREA; HYPONATREMIA; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SIDE EFFECT; WEIGHT REDUCTION;

ANIMALS; CELL DEATH; DISEASE MODELS, ANIMAL; HUMANS; MODELS, BIOLOGICAL; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES;

EID: 33644823299     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20794     Document Type: Editorial

References (26)

1. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal Glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59:459-466.
2. Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-1132.
3. Ai Y, Markesbery W, Zhang Z, et al. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol 2003;461:250-261.
4. Grondin R, Cass WA, Zhang Z, et al. Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J Neurosci 2003;23:1974-1980.
5. Grondin R, Zhang Z, Yi A, et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002;125:2191-2201.
6. Moore DJ, West AB, Dawson VL, et al. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005;28:57-87.
7. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69-73.
8. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-595.
9. Patel NK, Bunnage M, Plaha P, et al. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 2005;57:298-302.
10. Love S, Plaha P, Patel NK, et al. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 2005;11:703-704.
11. Slevin JT, Gerhardt GA, Smith CD, et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005;102:216-222.
12. Gash DM, Zhang Z, Ai Y, et al. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann Neurol 2005;58:224-233.
13. McRae C, Cherin E, Yamazaki TG, et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 2004;61:412-420.
14. Eslamboli A, Georgievska B, Ridley RM, et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 2005;25:769-777.
15. Kotzbauer PT, Lampe PA, Heuckeroth RO, et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 1996;384:467-470.
16. Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997;275:838-841.
17. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000;290:767-773.
18. Fjord-Larsen L, Johansen JL, Kusk P, et al. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp Neurol 2005;195:49-60.
19. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11:551-555.
20. Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998;51:583-586.
21. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997;49:1621-1630.
22. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 1996;46:1244-1249.
23. A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF Study Group (Phase III). Neurology 1999;52:1427-1433.
24. Safety of CERE-120 (AAV2-NTN) in subjects with idiopathic Parkinson's disease. Available at: http://clinicaltrials.gov/ct/show/NCT00252850?order=1. Accessed 1/12/06.
25. CERE-110 in subjects with mild to moderate Alzheimer's disease. Available at: http://clinicaltrials.gov/ct/show/NCT00087789?order=1. Accessed 1/12/06.
26. Bloch J, Bachoud-Levi AC, Deglon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004;15:968-975.